search
Back to results

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

Primary Purpose

Type II Diabetes

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Placebo
Sitagliptin
LEZ763
Sponsored by
Novartis Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type II Diabetes focused on measuring Healthy volunteers,, Diabetes, Glucose, Pharmacokinetics

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion criteria:

  • All subjects: (suggest this will reduce duplication)
  • Male or female aged 18-65 yr,
  • Subjects must weigh at least 50 kg to participate in the study. Body mass index (BMI) must be within the range of 18-37 kg/m2 (inclusive
  • Only postmenopausal females or female subjects who report surgical sterilization (women without child bearing potential) will be allowed in this study.
  • Subjects with stable conventional sleep-wake cycle

Normal Healthy Volunteers

  • Healthy male or female subjects,
  • must be in good health (as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at Screening).

Type II Diabetic Patients

  • Type 2 diabetes diagnosed by American Diabetes Association criteria for at least 3 months prior to screening.
  • Patients either drug naïve or on stable dose of metformin (stable dose for at least 4 weeks prior to Screening). The metformin dose should remain constant during the course of the study.
  • HbA1c 6.5 to 9.5 % inclusive at screening

Exclusion criteria:

All subjects:

  • Smokers (use of tobacco products in the previous 3 months).
  • Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing, or longer if required by local regulation.
  • Significant illness within two weeks prior to dosing.
  • Have (or have history of) drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by the laboratory assays conducted during the screening or baseline evaluations

Normal Healthy Volunteers

• History of diabetes, or adrenal disorders.

Type II Diabetic Patients

  • Type 1 diabetes mellitus; positive anti-GAD antibodies; acquired or secondary forms of diabetes such as those resulting from pancreatic surgery/injury, cystic fibrosis related diabetes
  • Evidence of clinically significant diabetic complications (such nephropathy, retinopathy, neuropathy) Other protocol defined inclusion/exclusion criteria may apply

Sites / Locations

  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Placebo Comparator

Active Comparator

Arm Label

LEZ763

Placebo

Sitagliptin

Arm Description

Part I- Healthy volunteers enrolled into 6 single-ascending dose cohorts Part II- Healthy volunteers enrolled into 5 multiple-ascending dose cohorts. Part III- LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner

Part I : Healthy volunteers enrolled in 6 single ascending dose cohorts to receive matching placebo of LEZ763. Part II: Healthy volunteers enrolled in 5 multiple ascending dose cohorts to receive matching placebo of LEZ763. Part III- Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner

Sitaglitpin will be given orally once daily for 28 days to patients assigned to this treatment in a randomized and blinded manner

Outcomes

Primary Outcome Measures

Number of Patients with adverse events, serious adverse events and death
An adverse event is the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. Adverse events will also be determined on the basis of clinical laboratory assessments, electrocardiographic evaluations and vital signs determinations.
Pharmacokinetics of LEZ763 (Part I): area under the plasma concentration-time curve from time zero to infinity (AUCinf)
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose
Pharmacokinetics of LEZ763 (Part I): area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose
Pharmacokinetics of LEZ763 (Part I): Terminal elimination half-life (T1/2)
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose
Pharmacokinetics of LEZ763 (Part I): Apparent systemic (or total body) clearance from plasma following extravascular administration (CL/F)
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose
Pharmacokinetics of LEZ763 (Part I) : Observed maximum plasma concentration (Cmax) following drug administration
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single and multiple doses
Pharmacokinetics of LEZ763 (Part I): time to reach the maximum concentration after drug administration (Tmax)
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose
Pharmacokinetics of LEZ763 (Part II) : Observed maximum plasma concentration (Cmax) following drug administration
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses
Pharmacokinetics of LEZ763 (Part II): time to reach the maximum concentration after drug administration (Tmax)
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses
Pharmacokinetics of LEZ763 (Part II): Accumulation ratio(Racc)
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses
Pharmacokinetics of LEZ763 (Part III) : Observed maximum plasma concentration (Cmax) following drug administration
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses
Pharmacokinetics of LEZ763 (Part III): time to reach the maximum concentration after drug administration (Tmax)
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses
Pharmacokinetics of LEZ763 (Part III): Area under the plasma concentration-time curve from time zero to the end of the dosing interval tau (AUCtau)
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single and multiple doses
Pharmacokinetics of LEZ763 (Part III): Accumulation ratio(Racc)
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single and multiple doses
Pharmacokinetics of LEZ763 and Sitagliptin (Part III): Observed maximum plasma concentration (Cmax) following drug administration
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses
Pharmacokinetics of LEZ763 and Sitagliptin (Part III): Area under the plasma concentration-time curve from time zero to the end of the dosing interval tau (AUCtau)
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses
Pharmacokinetics of LEZ763 and Sitagliptin (Part III): Time to reach the maximum concentration after drug administration (Tmax)
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses
Area under the effect curve (AUC0-4h) over the 4-hour post-dose period to measure glucose response following a standard mixed meal test

Secondary Outcome Measures

Area under the serum Glucagon-like-peptide 1 (GLP-1) curve (AUC0-24 hours)
GLP-1 Biomarker measures will be evaluated at pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose
2-hour value of post-prandial glucose
Change from baseline in Fasting C-peptide at Day 27 (Part III)
Change from baseline in Fasting Insulin at Day 27 (Part III)
Change from baseline in fasting plasma glucose at Day 27 (Part III)
Change From Baseline in peak glucose level following meal Test at Day 27 (Part III)
Peak effect (Emax) on postprandial GLP-1 (Part III)
Change from baseline in Peptide YY (PYY) (Part III)
Change from baseine in Gastric inhibit polypeptide (GIP) (Part III)

Full Information

First Posted
June 12, 2012
Last Updated
December 11, 2020
Sponsor
Novartis Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT01619332
Brief Title
Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763
Official Title
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763 Following Single and Multiple Ascending Doses in Healthy Subjects and Patients With Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
March 2016
Overall Recruitment Status
Completed
Study Start Date
March 2012 (undefined)
Primary Completion Date
September 2013 (Actual)
Study Completion Date
September 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis Pharmaceuticals

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is a three part study to assess the safety and efficacy of LEZ763 on normal healthy volunteers and patients with Type 2 Diabetes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type II Diabetes
Keywords
Healthy volunteers,, Diabetes, Glucose, Pharmacokinetics

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Enrollment
220 (Actual)

8. Arms, Groups, and Interventions

Arm Title
LEZ763
Arm Type
Experimental
Arm Description
Part I- Healthy volunteers enrolled into 6 single-ascending dose cohorts Part II- Healthy volunteers enrolled into 5 multiple-ascending dose cohorts. Part III- LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Part I : Healthy volunteers enrolled in 6 single ascending dose cohorts to receive matching placebo of LEZ763. Part II: Healthy volunteers enrolled in 5 multiple ascending dose cohorts to receive matching placebo of LEZ763. Part III- Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner
Arm Title
Sitagliptin
Arm Type
Active Comparator
Arm Description
Sitaglitpin will be given orally once daily for 28 days to patients assigned to this treatment in a randomized and blinded manner
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner
Intervention Type
Drug
Intervention Name(s)
Sitagliptin
Intervention Description
Sitaglitpin will be given orally once daily for 28 days to patients assigned to this treatment in a randomized and blinded manner
Intervention Type
Drug
Intervention Name(s)
LEZ763
Intervention Description
LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner
Primary Outcome Measure Information:
Title
Number of Patients with adverse events, serious adverse events and death
Description
An adverse event is the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. Adverse events will also be determined on the basis of clinical laboratory assessments, electrocardiographic evaluations and vital signs determinations.
Time Frame
Day 28
Title
Pharmacokinetics of LEZ763 (Part I): area under the plasma concentration-time curve from time zero to infinity (AUCinf)
Description
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose
Time Frame
pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4
Title
Pharmacokinetics of LEZ763 (Part I): area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)
Description
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose
Time Frame
pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4
Title
Pharmacokinetics of LEZ763 (Part I): Terminal elimination half-life (T1/2)
Description
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose
Time Frame
pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4
Title
Pharmacokinetics of LEZ763 (Part I): Apparent systemic (or total body) clearance from plasma following extravascular administration (CL/F)
Description
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose
Time Frame
pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4
Title
Pharmacokinetics of LEZ763 (Part I) : Observed maximum plasma concentration (Cmax) following drug administration
Description
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single and multiple doses
Time Frame
pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4
Title
Pharmacokinetics of LEZ763 (Part I): time to reach the maximum concentration after drug administration (Tmax)
Description
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose
Time Frame
pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4
Title
Pharmacokinetics of LEZ763 (Part II) : Observed maximum plasma concentration (Cmax) following drug administration
Description
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses
Time Frame
pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 10
Title
Pharmacokinetics of LEZ763 (Part II): time to reach the maximum concentration after drug administration (Tmax)
Description
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses
Time Frame
pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 10
Title
Pharmacokinetics of LEZ763 (Part II): Accumulation ratio(Racc)
Description
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses
Time Frame
pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27
Title
Pharmacokinetics of LEZ763 (Part III) : Observed maximum plasma concentration (Cmax) following drug administration
Description
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses
Time Frame
pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27
Title
Pharmacokinetics of LEZ763 (Part III): time to reach the maximum concentration after drug administration (Tmax)
Description
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses
Time Frame
pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27
Title
Pharmacokinetics of LEZ763 (Part III): Area under the plasma concentration-time curve from time zero to the end of the dosing interval tau (AUCtau)
Description
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single and multiple doses
Time Frame
pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27
Title
Pharmacokinetics of LEZ763 (Part III): Accumulation ratio(Racc)
Description
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single and multiple doses
Time Frame
pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27
Title
Pharmacokinetics of LEZ763 and Sitagliptin (Part III): Observed maximum plasma concentration (Cmax) following drug administration
Description
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses
Time Frame
pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose on Day 28
Title
Pharmacokinetics of LEZ763 and Sitagliptin (Part III): Area under the plasma concentration-time curve from time zero to the end of the dosing interval tau (AUCtau)
Description
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses
Time Frame
pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose on Day 28
Title
Pharmacokinetics of LEZ763 and Sitagliptin (Part III): Time to reach the maximum concentration after drug administration (Tmax)
Description
Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses
Time Frame
pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose on Day 28
Title
Area under the effect curve (AUC0-4h) over the 4-hour post-dose period to measure glucose response following a standard mixed meal test
Time Frame
4 hour post-dose Day 27
Secondary Outcome Measure Information:
Title
Area under the serum Glucagon-like-peptide 1 (GLP-1) curve (AUC0-24 hours)
Description
GLP-1 Biomarker measures will be evaluated at pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose
Time Frame
Pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose on Day -1, Day 1, Day 27, and Day 28
Title
2-hour value of post-prandial glucose
Time Frame
Day 1 of Part I, Day 1 and day 10 of Part II
Title
Change from baseline in Fasting C-peptide at Day 27 (Part III)
Time Frame
Baseline, Day 27
Title
Change from baseline in Fasting Insulin at Day 27 (Part III)
Time Frame
Baseline , Day 27
Title
Change from baseline in fasting plasma glucose at Day 27 (Part III)
Time Frame
Baseline , Day 27
Title
Change From Baseline in peak glucose level following meal Test at Day 27 (Part III)
Time Frame
Baseline , Day 27
Title
Peak effect (Emax) on postprandial GLP-1 (Part III)
Time Frame
Baseline , Day 27
Title
Change from baseline in Peptide YY (PYY) (Part III)
Time Frame
Baseline , Day 27
Title
Change from baseine in Gastric inhibit polypeptide (GIP) (Part III)
Time Frame
Baseline , Day 27

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria: All subjects: (suggest this will reduce duplication) Male or female aged 18-65 yr, Subjects must weigh at least 50 kg to participate in the study. Body mass index (BMI) must be within the range of 18-37 kg/m2 (inclusive Only postmenopausal females or female subjects who report surgical sterilization (women without child bearing potential) will be allowed in this study. Subjects with stable conventional sleep-wake cycle Normal Healthy Volunteers Healthy male or female subjects, must be in good health (as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at Screening). Type II Diabetic Patients Type 2 diabetes diagnosed by American Diabetes Association criteria for at least 3 months prior to screening. Patients either drug naïve or on stable dose of metformin (stable dose for at least 4 weeks prior to Screening). The metformin dose should remain constant during the course of the study. HbA1c 6.5 to 9.5 % inclusive at screening Exclusion criteria: All subjects: Smokers (use of tobacco products in the previous 3 months). Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing, or longer if required by local regulation. Significant illness within two weeks prior to dosing. Have (or have history of) drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by the laboratory assays conducted during the screening or baseline evaluations Normal Healthy Volunteers • History of diabetes, or adrenal disorders. Type II Diabetic Patients Type 1 diabetes mellitus; positive anti-GAD antibodies; acquired or secondary forms of diabetes such as those resulting from pancreatic surgery/injury, cystic fibrosis related diabetes Evidence of clinically significant diabetic complications (such nephropathy, retinopathy, neuropathy) Other protocol defined inclusion/exclusion criteria may apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Novartis Investigative Site
City
Chula Vista
State/Province
California
ZIP/Postal Code
91910
Country
United States
Facility Name
Novartis Investigative Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33126
Country
United States
Facility Name
Novartis Investigative Site
City
Orlando
State/Province
Florida
ZIP/Postal Code
32809
Country
United States
Facility Name
Novartis Investigative Site
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45227
Country
United States
Facility Name
Novartis Investigative Site
City
Knoxville
State/Province
Tennessee
ZIP/Postal Code
37920
Country
United States
Facility Name
Novartis Investigative Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78209
Country
United States

12. IPD Sharing Statement

Links:
URL
https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12503
Description
Results for CLEZ763X2201 from the Novartis Clinical Trials website

Learn more about this trial

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

We'll reach out to this number within 24 hrs